Elizabeth Schneider: Revolutionary Drug Shows Promise for Primary Ovarian Insufficiency
Elizabeth Schneider, Staff Product Marketing Manager at Illumina, shared a post on LinkedIn:
“Primary ovarian insufficiency (POI), in which the ovaries don’t mature and release eggs properly, affects about 3% of women under age 40 and typically causes infertility. But a drug already approved to treat kidney disease may one day help some of these people get pregnant, a research team reports today in Science.
In studies of mouse ovarian tissue and live mice, the drug, called finerenone, kick-started the growth of tiny egg-containing sacs, or follicles—a process that’s often defunct in people with POI. In a small clinical trial, people with POI who were given the drug went on to produce mature eggs that could be harvested, and some of the eggs were then successfully fertilized in the lab.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Jul 15, 2026, 15:57Early Bird Registration Opens for RCOG Female Reproductive Physiology Course – RCOG
-
Jul 15, 2026, 15:53ACOG Joins Coalition to Advance National Women’s Health Strategy – ACOG
-
Jul 15, 2026, 15:44From the Shadow of Pregnancy Loss to a New Pregnancy – RBMO
-
Jul 15, 2026, 15:27Supporting the Launch of the National Strategy to Close the Women’s Health Gap – ASRM
-
Jul 15, 2026, 15:21Sergio Haimovich: AI Is Already Reshaping Scientific Publishing and Disclosure Is Lagging Behind
-
Jul 15, 2026, 15:12The Egg’s Engine Is Fed Plenty of Fuel, It Just Can’t Burn It – Fertility Plus
-
Jul 15, 2026, 15:07Join the Ultrasound in Obstetrics and Gynecology Team as the UOG Social Media Editor – ISUOG
-
Jul 15, 2026, 14:56Can Ultrasound Reliably Detect Residual Cervical Cancer After Conization? – IJGC
-
Jul 15, 2026, 14:27Marco Zaccaria: A Great Webinar, Hosted By BSGE and BMUS